Swedish Orphan Biovitrum AB (publ) logo

SOBI - Swedish Orphan Biovitrum AB (publ) Share Price

SEK183.1 -9.6  -5.0%

Last Trade - 3:05pm

Sector
Healthcare
Size
Large Cap
Market Cap £4.50bn
Enterprise Value £5.76bn
Revenue £1.13bn
Position in Universe 120th / 1714
Bullish
Bearish
Unlock SOBI Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SOBI Revenue Unlock SOBI Revenue

Net Income

SOBI Net Income Unlock SOBI Revenue

Normalised EPS

SOBI Normalised EPS Unlock SOBI Revenue

PE Ratio Range

SOBI PE Ratio Range Unlock SOBI Revenue

Dividend Yield Range

SOBI Dividend Yield Range Unlock SOBI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SOBI EPS Forecasts Unlock SOBI Revenue
Profile Summary

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Public Since September 15, 2006
No. of Shareholders: n/a
No. of Employees: 1,275
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Euromid ,
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 294,299,740
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SOBI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SOBI
Upcoming Events for SOBI
Wednesday 29th April, 2020
Q1 2020 Swedish Orphan Biovitrum AB (publ) Earnings Release
Wednesday 13th May, 2020
Swedish Orphan Biovitrum AB (publ) Annual Shareholders Meeting
Thursday 16th July, 2020
Q2 2020 Swedish Orphan Biovitrum AB (publ) Earnings Release
Similar to SOBI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.